UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2016

FENNEC PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

001-32295
(Commission File Number)

Registrant’s telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 8, 2016, Fennec Pharmaceuticals Inc. (the “Company”) held an annual and special meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

1. The following four (4) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

2. The resolution to re-appoint Deloitte LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

4. The resolution to vote for the approval of unallocated stock options was approved based on the following vote:

5. The resolution to vote for the approval of amendments to the stock option plan was approved based on the following vote:

6. The resolution to vote for the approval of extension of options was approved based on the following vote:

7. The resolution to vote for the approval of sale of certain assets was approved based on the following vote:

Item 8.01 Other Events.

On June 6, 2016, Fennec Pharmaceuticals Inc. issued a press release announcing the interim results of SIOPEL 6 study on sodium thiosulfate (STS) presented at the American Association of Clinical Oncology (ASCO) 2016 meeting in Chicago, Illinois. A copy of the press release is filed as Exhibit 99.1 to this Current Report Form 8-K.

Item 9.01 Financial Statement and Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.